Gene therapy

#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy

Under the microscope: Zoning in on the CGT sector

Listen to this article on the DDW Podcast: IB Communications’ CEO Michelle Boxall explains why there are two sides to the cell and gene therapy coin. Charles Dickens’ quote, “It was the best of times, it was the worst of times”, aptly describes the complexity surrounding CGT financing. With 2023’s financial… Read More

#Exclusive Content #Opinion

DNA vector
#Cell and gene therapy #FDA #Gene therapy #Muscular dystrophy #Sarepta Therapeutics

FDA committee supports gene therapy for muscular dystrophy

The US Food and Drug Administration (FDA) Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) have voted eight to six in favour of a new gene therapy for Duchenne muscular dystrophy. The vote supports the accelerated approval of Sarepta Therapeutics’ SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulatory patients with… Read More

#News #Regulatory #Trending News

#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy

Understanding the future roadmaps of cell and gene therapy

Listen to this article on the DDW Podcast: DDW’s Megan Thomas caught up with George White, General Manager, Product Management, Cell & Gene Therapy at Cytiva, to learn more about the company’s insight into the CGT market. Key challenges for cell and gene therapies In order for cell and gene (CGT) therapies… Read More

#Exclusive Content #Opinion

#Advanced Therapies #CAR-T #Cell and gene therapy #Cell therapy #Gene therapy

No sign of stopping: The rise of cell and gene therapy

Listen to this article on the DDW Podcast: Ryan Leahy, a science communication expert in cell and gene therapy, at Phacilitate, says there is a lot to celebrate but also much to assess, question and challenge in this sector. While the global economic landscape faces a major crisis and biotech is… Read More

#Exclusive Content #Opinion

Pancreatic cancer concept
#Biotechnology #Cancer research #Drug development #Drug discovery #Gene therapy #Oncology

How this biotech is looking to collaboration to treat pancreatic cancer

DDW Editor Reece Armstrong speaks to Howard Davis, CEO of clinical stage oncology company, Akamis Bio, about its work in developing a gene therapy to treat pancreatic cancer.    In February this year, Akamis Bio announced an expansion of its ongoing partnership with the Parker Institute for Cancer Immunotherapy (PICI) to include… Read More

#Exclusive Content

#Aptamer Group #Aptamers #Automation #Drug delivery #Gene delivery #Gene therapy #Molecular Biology #Oncology #Precision medicine #Turning Science into Business

Turning science into business: An optimised alternative to antibodies

From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley. DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would… Read More

#Exclusive Content

Haematology
#Cell and gene therapy #CSL #Gene therapy #Haemophilia #MHRA #Phase III trial

First gene therapy for haemophilia B approved in Great Britain

CSL’s Hemgenix (etranacogene dezaparvovec) has been authorised as the first gene therapy for adults with severe and moderately severe haemophilia B (congenital Factor IX (FIX) deficiency) in Great Britain. It has been granted a marketing authorisation for patients without a history of FIX inhibitors by the UK Medicines and Healthcare… Read More

#News #Regulatory

Disabled patient having rehabilitation
#Gene therapy #Genetic diseases #Genetics / genomics #Muscles

Researchers discover treatment for rare muscle disease

Israeli researchers have developed a drug that is effective in treating a rare genetic muscle disease. The research team from Ben-Gurion University of the Negev and Soroka Medical Center discovered the severe hereditary muscle disease that develops around the age of 40 years, progressing to complete… Read More

#News

#Cancer research #Clinical trial design #Clinical trials #Drug discovery #Gene therapy #Oncology

Podcast: Key stories from the drug discovery industry

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Perhaps most interestingly this week, after previous caution over in vivo… Read More

#News

Woman having an eye test
#Cell and gene therapy #Clinical trials #Gene therapy #Genetics / genomics #GenSight Biologics #Ophthalmology

Five-year data show gene therapy safe for ND4-LHON

GenSight Biologics has revealed pooled safety data from five clinical studies of lenadogene nolparvovec (Lumevoq), the largest cohort of ND4-LHON (Leber hereditary optic neuropathy) patients studied after gene therapy treatment. The data confirms the good overall safety profile of the product in terms of systemic and… Read More

#News

#Cancer research #Clinical trial design #Clinical trials #Drug discovery #Gene therapy #Oncology

This week in drug discovery (6-10 March)

News round-up for 6-10 March by DDW Digital Content Editor Diana Spencer.  Perhaps most interestingly this week, after previous caution over in vivo gene therapy trials, the FDA has given the go ahead to Intellia Therapeutics to study NTLA-2002 in hereditary angioedema (HAE).  There have been several… Read More

#News

#Clinical trial #CRISPR #FDA #Gene editing #Gene therapy #In vivo #Intellia Therapeutics

FDA clears in vivo gene editing therapy for trials in US

The US Food and Drug Administration (FDA) has cleared Intellia Therapeutics’ Investigational New Drug (IND) application for NTLA-2002 for the treatment of hereditary angioedema (HAE).  Intellia is a clinical-stage genome editing company focused on developing potentially curative therapies using CRISPR-based technologies.   The decision will enable the company to include the… Read More

#News #Regulatory #Trending News

Gene therapy
#AAV #EMA #Gene therapy #Genethon #Genetic diseases #Liver disease #Priority Review

Gene therapy for rare liver disease gets EMA priority status

The European Medicines Agency (EMA) has granted PRIME (Priority Medicines) status to the gene therapy, GNT-0003, currently in clinical trials for Crigler-Najjar syndrome, a rare liver disease.   This status, granted only to drug candidates with major therapeutic potential, follows the successful completion of the first phases of the clinical trials. … Read More

#Editor's Choice #News #Regulatory

Plague bacterium Yersinia pestis, scientifically accurate 3D illustration showing structure of the cell with DNA, plasmids and ribosomes
#Cancer research #CureLab Oncology #Gene therapy #Investment #Oncology #Plasmid DNA

Oncology company receives $3M from biotech investor

Dr John Ballantyne, co-founder of Aldevron, has invested $3 million in CureLab Oncology and CureLab Veterinary. The two sister companies have developed an anti-cancer and anti-inflammatory drug that was contract-manufactured by Aldevron at the time Dr Ballantyne served there as chief scientific officer. Both CureLab Oncology and CureLab Veterinary are… Read More

#Business & Investment #News

Genetic engineering
#Cell and gene therapy #CNS #Gene editing #Gene therapy #Genetics / genomics #Paediatrics #Stem cells

Gene therapy for ‘childhood dementia’ shows promise

An investigational gene therapy for Sanfilippo syndrome – which leads to a form of childhood dementia – has shown promising early results in a proof-of-concept study.  The study found that four out of five patients diagnosed with Sanfilippo have continued to gain cognitive skills in line with… Read More

#Editor's Choice #News

Screening patient for AMD
#Clinical research #Complement Therapeutics #Dry AMD #Gene therapy #Geographic atrophy #Ophthalmology

Non-interventional geographic atrophy study launches

Complement Therapeutics (CTx) has enrolled the first patient in its study of people diagnosed with geographic atrophy (GA).  The research will support the clinical development of CTx001, CTx’s lead gene therapy asset for the treatment of GA, by enabling the identification of patients with complement-driven AMD for future… Read More

#News